Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The assumption has been that 1,25(OH)2D is solely responsible for calcium absorption. That has been one of the presumed causes of hyperparathyroidism in chronic kidney disease (CKD) (low 1,25(OH)2D leads to decreased calcium absorption, which increases parathyroid hormone release in compensation). Replacing 1,25 D directly has been the goal with using 1,25D or its analogues in CKD. There is very little data concerning use of native vitamin D or 25(OH)D in CKD, although autocrine functions in extrarenal tissues would use 25(OH)D. The latest KDIGO guidelines do recognize the autocrine role of vitamin D, but have no data on outcomes or doses or optimal levels to guide them and so have made a blanket recommendation to treat 25D levels in CKD by general healthy population guidelines.

1. This project focuses on an outcome (calcium absorption) that may be impacted by optimizing 25D status in renal patients. The investigators will assume for this project that a level of 25D \> 32 ng/ml is optimal in CKD patients as in a healthy population.
2. A secondary outcome is to quantify calcium absorption in CKD patients with and without vitamin D repletion and to quantify systemic 1,25D levels. This may clarify the roles 25D and 1,25D play in calcium absorption.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney Disease Patients on Chronic Hemodialysis

NCT01675557

Chronic Kidney Disease

COMPLETED PHASE4

Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease

NCT01835691

Chronic Kidney Disease

COMPLETED NA

Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients

NCT01173848

Chronic Kidney Disease Stage 3 and 4

TERMINATED PHASE3

Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD

NCT02005718

CKd Patients With Stage 3 and 4

COMPLETED PHASE3

Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients

NCT05667090

Hemodialysis Chronic Pain Hyperparathyroidism

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease End Stage Renal Disease Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cholecalciferol

a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Maximum D3, cholecalciferol, 10,000IU/capsule, 0.25mg USP, Pro-Pharma LLA, Kirksville, Mo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* on hemodialysis
* \> 19 years of age

Exclusion Criteria

* Pregnancy or planned pregnancy
* Hypercalcemia (\> 10.2 mg/dl) at baseline
* Chronic GI disease
* Liver dysfunction
* Taking steroids
* Received any investigational drugs within 4 weeks
* Any allergy to vitamin D3
* Chronic vitamin D intake \> 1,000 IU daily
* Dialysate concentration (calcium 2.5mg/L) which is to remain constant during Rx

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No